Liquidia utilizes a proprietary platform technology to design, develop, and manufacture precisely engineered nanoparticles and patterned films for high-value applications in Engineered Drug Therapies™ and Optical Films. The PRINT® (Pattern Replication In Non-wetting Templates) platform utilizes techniques from the microelectronics industry to design and manufacture highly-precise shape and size-specific nanomaterials.
In the life sciences sector, Liquidia is using the PRINT platform to develop Engineered Drug Therapies™, precisely engineered nanoparticles for the delivery of biological and small molecule therapeutics to treat a range of diseases. Liquidia's ability to independently control the shape, size, surface functionalization, and deformability of the particles enables highly-effective targeting, controlled release, and enhanced efficacy of the therapeutic cargo. The unique shapes of PRINT particles also lead to the enhanced ability to cross biological barriers and be taken up by target cells and tissues.
In the materials science sector, Liquidia is using PRINT technology to develop nano-precise Optical Films for displays. The ability to manipulate light with Liquidia's nano-patterned optical films enable brighter, thinner, cost-effective, and energy efficient displays for our customers and consumers
|
|
Recent News
August 6, 2008 - Shape is key in nanomedicine  Details
July 14, 2008 - Liquidia presents at Controlled Release Society Annual Meeting Details
June 25, 2008 - $500,000 Lemelson-MIT Prize awarded to Liquidia founder Details
June 18, 2008 - Liquidia CEO to present at BIO Business Forum. Details
June 2008 - Liquidia scientists develop material for NASA ExoMars rover. Details
May 2008 - Liquidia's precision nano-molding of protein particles highlighted in Nature Materials. Details
May 2008 - Precision nano-molding of protein particles highlighted in Nature Materials. Details
March 11, 2008 - Liquidia Announces Seth Rudnick as Chairman of the Board. Details
March 5, 2008 - Liquidia Announces Neal Fowler as CEO. Details
| |
